Efficacy and safety of rotigotine transdermal patch for Parkinson’s disease：a systematic review

Zhou Changqing; Gao Chang; Chen Yalan; Peng Guoguang

您当前的位置：

首页 >

文章列表页 >

Efficacy and safety of rotigotine transdermal patch for Parkinson’s disease：a systematic review

更新时间：2023-12-18

- Efficacy and safety of rotigotine transdermal patch for Parkinson’s disease：a systematic review
- Journal of Chongqing Medical University Vol. 40, Issue 5, Pages: 736-742(2015)
- 作者机构：
  
  1. 重庆市璧山区人民医院神经内科,重庆,402760
  2. 重庆医科大学附属第一医院神经内科,重庆,400016
- 作者简介：
- 基金信息：
- DOI：
  CLC：
- Published：2015，
扫描看全文
Zhou Changqing, Gao Chang, Chen Yalan, et al. Efficacy and safety of rotigotine transdermal patch for Parkinson’s disease：a systematic review. [J]. Journal of Chongqing Medical University 40(5):736-742(2015)
DOI：

Zhou Changqing, Gao Chang, Chen Yalan, et al. Efficacy and safety of rotigotine transdermal patch for Parkinson’s disease：a systematic review. [J]. Journal of Chongqing Medical University 40(5):736-742(2015) DOI：

摘要

目的：运用Meta分析的方法，系统评价罗替戈汀透皮贴剂在帕金森病（Parkinson’s disease，PD）中的有效性、耐受性和安全性。方法：系统地检索PubMed，Cochrane图书馆，EMBASE和Web of Knowledge等数据库有关罗替戈汀透皮贴剂治疗PD的随机对照试验，采用Rev Man 5.1软件对数据进行分析。结果：（1）共纳入7个随机对照研究，1 969例患者。（2）Meta分析结果显示：①有效性：罗替戈汀透皮贴剂在减少统一帕金森病评估量表Ⅱ部分评分（WMD=-1.69，95%CI=-2.18 to -1.19，P=0.000）和Ⅲ部分评分（WMD=-3.86，95%CI=-4.86 to -2.86，P=0.000）上均优于安慰剂。②耐受性：罗替戈汀透皮贴剂较安慰剂不增加患者总的退出风险（RR=0.88，95%CI=0.64～1.21，P=0.44），但增加患者因为不良事件退出的风险（RR=1.82，95%CI=1.29~2.59，P=0.000）。③安全性：罗替戈汀透皮贴剂较安慰剂增加局部皮肤反应（RR=2.77，95%CI=2.23~3.43，P=0.000）、呕吐（RR=6.15，95%CI=2.88～13.13，P=0.000）及异动症（RR=2.52，95%CI=1.47～4.32，P=0.000）的发生风险。结论：罗替戈汀透皮贴剂能有效的控制PD患者的症状，但也增加了局部皮肤反应等不良事件的发生风险。

Abstract

Objective：To evaluate the efficacy，tolerability，and safety of rotigotine transdermal patch in Parkinson’s disease. Methods：The PubMed，Cochrane Library databases，EMBASE，and Web of Knowledge were searched for the randomized clinical trial（RCT） of rotigotine transdermal patch in Parkinson’s disease. RevMan 5.1 software was used to analyze the data. Results：（1） Seven large-scale RCTs，involving 1 969 patients were included in this meta-analysis. （2）The results showed：①Efficacy：compared with placebo，the use of rotigotine resulted in greater improvement in UPDRS Ⅱ score（WMD=-1.69，95%CI=-2.18 to -1.19，P=0.000） and Ⅲ score（WMD=-3.86，95%CI=-4.86 to -2.86，P=0.000）. ②Tolerability：no difference was found in overall withdrawals（RR=0.88，95%CI=0.64 to 1.21，P=0.44），but rotigotine was associated with a significantly higher rate of withdrawals due to adverse events（RR=1.82，95%CI=1.29 to 2.59，P=0.000）. ③Safety：rotigotine was associated with a significantly higher rate of application site reactions（RR=2.77，95%CI=2.23 to 3.43，P=0.000），vomiting（RR=6.15，95%CI=2.88 to 13.13，P=0.000），and dyskinesia（RR=2.52，95%CI=1.47 to 4.32，P=0.000） compared with placebo. Conclusion：The use of rotigotine can reduce the symptoms of PD. However，rotigotine is also associated with a higher incidence of adverse events，especially application site reactions.

关键词

罗替戈汀透皮贴剂帕金森病系统评价

Keywords

rotigotine transdermal patchParkinson’s diseasesystematic review

references

Views

617

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

A systematic review of early oral refeeding versus conventional oral refeeding for acute pancreatitis

Effects of endometrial polyps and polypectomy on pregnancy rates of infertility patients:a systematic review

Coffee consumption and risk of gallstone disease:a systematic review

Transanal endoscopic microsurgery versus traditional transanal excision for rectal neoplasms:systematic review

Analysis of weight change and its related factors of Parkinson’s disease patients

Related Author

Wang Qiang

Du Tao

Ding Xiong

Niu Jingya

Gu Nihao

Yuan Rui

Chen Lanfang

Hu Zhen

Related Institution

Department of Nephrology,the Second Affiliated Hospital,Chongqing Medical University

Department of Hepatobiliary Surgery,the Second Affiliated Hospital,Chongqing Medical University

Department of Obstetrics and Gynecology,International Peace Maternity and Child Health Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Department of Gynecology,The First Affiliated Hospital of Chongqing Medical University

Institute of Gastroenterology,Southwest Hospital,Third Military Medical University

⁰